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ABSTRACT
Detection of anti-toxoplasma IgM antibodies has frequently been used as a serological marker for diagnosing recently acquired toxoplasmosis. However, 
the persistence of these antibodies in some patients has complicated the interpretation of serological results when toxoplasmosis is suspected. The 
purpose of the present study was to evaluate the avidity of IgG antibodies against excreted/secreted antigens of Toxoplasma gondii by means of 
immunoblot, to establish a profile for acute recent infection in a single serum sample and confirm the presence of residual IgM antibodies obtained in 
automated assays. When we evaluated the avidity of IgG antibodies against excreted/secreted antigens of Toxoplasma gondii by means of immunoblot, 
we observed phase-specific reactivity, i.e. cases of acute recent toxoplasmosis presented low avidity and cases of non-acute recent toxoplasmosis 
presented high avidity towards the 30kDa protein fraction, which probably corresponds to the SAG-1 surface antigen. Our results suggest that the 
avidity of IgG antibodies against excreted/secreted antigens of Toxoplasma gondii is an important immunological marker for distinguishing between 
recent infections and for determining the presence of residual IgM antibodies obtained from automated assays.  
Key-words: Toxoplasmosis. Serology. Avidity. Excreted/secreted antigens. 
RESUMO
A detecção de anticorpos IgM antitoxoplasma tem sido freqüentemente utilizada como marcador sorológico para o diagnóstico de toxoplasmose de 
aquisição recente. Entretanto, a persistência destes anticorpos em alguns pacientes tem complicado a interpretação dos resultados sorológicos quando 
a toxoplasmose é suspeitada. A proposta deste trabalho foi avaliar a avidez de anticorpos IgG contra antígenos de secreção e excreção de Toxoplasma 
gondii por immunoblot, para estabelecer um perfil de infecção recente aguda em uma única amostra de soro e confirmar a presença de anticorpos 
IgM residuais obtidos nos testes automatizados. Quando a avidez de anticorpos IgG contra antígenos de secreção e excreção Toxoplasma gondii,
por immunoblot, foi avaliada, observou-se reatividade estágio específica, ou seja, casos de toxoplasmose aguda recente apresentaram baixa avidez e 
os casos de infecção recente não aguda apresentaram alta avidez para a fração protéica de 30kDa, que corresponde provavelmente ao antígeno de 
superfície- SAG-1. Nossos resultados sugerem que a avidez dos anticorpos IgG contra antígenos de secreção e excreção Toxoplasma gondii é um 
importante marcador imunológico para distinguir doença recente de infecção e determinar a presença de anticorpos IgM residuais detectados nos 
testes automatizados.
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Toxoplasmosis is caused by an intracellular parasite, 
Toxoplasma gondii, which presents global distribution and varying 
epidemiological characteristics among different populations. The 
course of infection by Toxoplasma gondii is generally benign, 
since the vast majority of infected patients remain asymptomatic 
or only present mild symptoms. However, the infection can cause 
significant morbidity and mortality in developing fetuses and in 
immunocompromised individuals4.
Toxoplasmosis is generally diagnosed by demonstrating 
specific antibodies to Toxoplasma antigens in serum samples from 
infected patients. Serological diagnoses of acute toxoplasmosis 
have traditionally been made by detecting IgM antibodies or 
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by demonstrating significant increases in specific IgG antibody 
levels, or both. However, because of the prevalence of high IgG 
Toxoplasma antibody titers in normal subjects and IgM antibodies 
detected several months or even years after acute infection in 
some individuals, interpretation of serological tests may be 
troublesome when acute toxoplasmosis is suspected13. Since 
IgG avidity evaluations for Toxoplasma infection serodiagnosis 
were introduced, this method has proved to be a highly useful 
procedure, especially in combination with conventional 
serological assays19 20. However, low-avidity results do not rule out 
the possibility of recently acquired infection, because low avidity 
may persist for as long as one year following the acute infection 
and low or borderline avidity can occur in significant numbers 
of patients without specific IgM antibodies2. Several reports have 
emphasized the value of detecting specific antibodies against 
excreted/secreted antigens (ESAs) of Toxoplasma gondii for 
diagnosing acute toxoplasmosis5 9 12 20. Toxoplasma gondii ESAs
constitute 90% of the circulating antigens in infected humans and 
thus are one of the first targets of the host immune response13 19. In 
our laboratory, we have recently developed a technique to obtain 
ESAs by incubating tachyzoites in human fibroblast cultures for a 
short period of time. In the present study, we evaluated IgG avidity 
against Toxoplasma gondii ESAs by means of immunoblot, in 
order to establish a profile for acute recent infection in single 
serum samples and to determine the presence of residual IgM 
antibodies detected in automated assays.
MATERIAL AND METHODS
Serum samples. One hundred and eighty serum samples 
were obtained from individuals during routine screening for 
toxoplasmosis and were analyzed using commercially available 
kits (VIDAS and AxSYM) to detect IgM and IgG antibodies 
against Toxoplasma gondii and specific IgG antibody avidity. 
These human serum samples were characterized using the 
classical serological methods of indirect immunofluorescence 
(IIF) and indirect hemagglutination (IHA) and by means of an 
automated system (VIDAS) to define study groups as follows: 
group I: 36 serum samples from patients suspected of recently 
acquired (acute) Toxoplasma gondii infection; group II: 61 
serum samples from patients suspected of recently acquired but 
non-acute Toxoplasma gondii infection; group III: 39 serum 
samples from patients with chronic toxoplasmosis; and group 
IV: 44 serum samples with negative serology, which were taken 
to be healthy controls. In addition, group V consisting of 20 
patients characterized serologically and clinically with rubella, 
mononucleosis and cytomegalovirus was included in this study in 
order to test the specificity of the method. Details of the specific 
serological tests for characterizing study groups I, II, III, IV and 
V are described in Table 1. The institution’s ethics committee 
approved the project. 
Serological tests. The serum samples had been routinely 
tested using two automated assays: AxSYM IgG and IgM (Abbott 
Laboratories, USA) and VIDAS Toxo IgG, IgM and IgG avidity 
(BioMérieux, Brazil); and using two non-automated methods: 
indirect immunofluorescence (IIF) (BioMérieux, Brazil) and 
indirect hemagglutination (IHA) (BioMérieux, Brazil). The avidity of 
Toxoplasma gondii-specific IgG antibodies was determined as previously 
described by Hedman et al9. All commercially available reagents were 
used in accordance with the manufacturer’s instructions.
Excreted/secreted antigen. RH-strain tachyzoites of 
Toxoplasma gondii were obtained from the peritoneal cavities 
of Balb/c mice that had been infected two days earlier, and 
were inoculated into human fibroblast cell cultures, for 3h at 
37°C. The culture supernatants were centrifuged at 1,000g for 
10 minutes and were filtered through membranes of pore size 
0.22Pm (Millipore Corporation, Bedford, MA, USA). The ESAs
were stored at -70°C with 100U/ml aprotinin (Sigma Chemical 
Co, St. Louis, MO, USA). To determine the mean number of 
intracellular parasites in host cells after 3h at 37°C, fibroblast cell 
cultures were trypsinated and counted in a Neubauer chamber.
Kinetics of ESA production. After washing three times 
with PBS at pH 7.2, the human fibroblast cultures were inoculated 
with 1 x 108 tachyzoites and incubated at 37°C. Five-milliliter 
aliquots of culture were taken at various times from one to 24 
hours post-infection. Supernatants obtained at various times from 
the cultures were evaluated regarding the numbers and viability of 
tachyzoites by means of trypan blue and the protein concentrations 
were determined using the Bio-RAD DC Protein Assay, France.
Immunoblotting of IgG antibodies against ESA 
antigens. The ESAs were subjected to electrophoresis on 
polyacrylamide gels using a discontinuous sodium dodecyl sulfate 
(SDS) buffer system as described by Laemmli15, with 18% running 
gel and 3% stacking gel. The running buffer contained 25mM TRIS, 
Table 1 - Details of the specific serological tests for characterizing study 
groups I, II, III, IV and V.
Group Number Description
Group I 36 Serum samples from these patients exhibited specific 
(acute)  IgM antibodies (titer >64), IgG antibodies (titer >256)
using IIF and IHA, and low avidity of T. gondii-specific
IgG. Serum samples were positive for T. gondii-specific
IgG and IgM using VIDAS. Three serum samples exhibited
an “acute” serological profile without clinical manifestation.
Group II 61 Samples had specific IgM antibodies (titer>64),
(recent non-acute)  associated with positive results for IgG (titer of >64) 
using IIF and IHA, and high avidity of T. gondii-specific
IgG. Serum samples were positive for T. gondii-specific
IgG and IgM using VIDAS. 
Group III 39 Serum samples exhibited specific IgG antibodies 
(chronic)  (titer >64), negative results for T. gondii-specific 
IgM-(titer <16) using IIF and high avidity of T. gondii
specific IgG. Serum samples were positive for IgG and
negative for IgM T. gondii-specific using VIDAS.
Group IV 44 All serum samples in this group were negative for
(healthy controls)  Toxoplasma-specific IgM and IgG using IIF and IHA.
Group V 20 Seven serum samples from individuals infected with 
(other diseases)  Epstein-Barr, six serum samples from patients infected 
with rubella virus and seven serum samples from
individuals infected with cytomegalovirus were tested.
IIF: indirect immunofluorescence assay, IHA: indirect hemagglutination.
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192mM glycine, and 0.1% SDS at pH 8.3. Gels were run at 5-6 
V/cm until the bromophenol blue marker reached the bottom. 
Molecular weight markers (Full Range RainbowTM, Amersham 
Life Sciences, England) were used to plot the calibration curve. 
Proteins separated by gel electrophoresis were further transferred 
to a 0.45Pm (pore size) nitrocellulose membrane overnight, 
using a semidry transfer system. After transfer, nitrocellulose 
strips were blocked with 5% skimmed milk (Molico, Nestlé) 
in PBS plus 0.05% T20 for 2h at room temperature, in order to 
saturate protein-binding sites. Strips were further incubated for 
18h at 4°C with serum samples, diluted 1:25 in 1% skimmed 
milk with PBS T20. After incubation, the strips were washed with 
PBS plus 0.05% Tween 20 three times for 5 min and incubated 
for 2h at room temperature with a 1:500 dilution of conjugate 
anti-human IgG-peroxidase (Sigma Chemical Co, St Louis, MO, 
USA) in PBS T20. After six washings with PBS plus 0.05% Tween 
20, the strips were treated with 3mg of 4-chloronaphthol (Sigma 
Chemical Co, St Louis, MO, USA) in 10ml of methanol and 4Pl of 
hydrogen peroxide. 
IgG-avidity of ESA antigen by means of immunoblotting.
Strips were incubated with serum samples, in duplicate, diluted 1:25 
into 1% skimmed milk in PBS plus 0.05% Tween 20 overnight at 
4°C. One strip of the duplicate was washed with PBS plus 0.05% T20 
three times for 5 min. The second nitrocellulose strip was washed 
with 8M urea solutions in PBS, three times for 5 min. Both strips 
were incubated with conjugate anti-human IgG-peroxidase (Sigma 
Chemical Co, St Louis, MO, USA) diluted at 1:500 in PBS plus 0.05% 
Tween 20 for 2h at room temperature. After a further washing step, 
repeated six times for 5 min in PBS, the strips were treated with 
3mg of 4-chloronaphthol (Sigma Chemical Co, St Louis, MO, USA) 
in 10ml of methanol and 4Pl of hydrogen peroxide. 
Avidity of Toxoplasma gondii-specific IgG by means 
of ELISA. The avidity of Toxoplasma gondii IgG antibodies was 
determined as described by Hedman9, with some modifications. 
Microtiter plates were previously coated with 105 tachyzoites/well 
obtained from peritoneal exudates of Balb/c mice that had been 
infected two days earlier with the RH strain of Toxoplasma gondii.
Serum samples were then added in duplicate, diluted 1:16 in PBS on 
separate plates. After incubation for 45 min at 37°C, the plates were 
subjected to differential washing methods as follows: one plate was 
washed with 8M urea solution in PBS for 5 min, while the other plate 
was washed only with PBS T20 for 5 min. In addition, both plates 
were washed twice with PBS T 20 for 5 min. Conjugate anti-human 
IgG-peroxidase (Sigma Chemical Co, St Louis, MO, USA) diluted at 
1:3,000 in PBS T20 and incubated for 45 min at room temperature 
was added. After three washes in PBS, the reaction was developed 
using a substrate solution consisting of orthophenylenediamine at 
0.5mg/ml in 0.1M citrate-phosphate buffer (pH 5.0) and 0.012% 
H
2
O
2
. After incubation for 15 min at room temperature, the reaction 
was stopped with 2N H
2
SO
4
. The absorbance was measured at 
492nm by using a plate reader system (Titertek Multiskan Plus, 
Geneva, Switzerland). The avidity index was calculated as the ratio 
between the absorbance obtained for the plate washed with PBS plus 
urea and the absorbance for the plate washed with PBS without 
urea and was expressed as a percentage. 
RESULTS
Non-automated serological assays. Out of the 200 human 
serum samples, 133 samples were positive for IgG-IIF and IgG-
IHA, 97 samples were positive for IgM-IIF and IgM-IHA, both 
with antibody titers >16. All other serum samples from patients 
with heterologous infections (rubella, cytomegalovirus and 
mononucleosis) had negative specific IgG and IgM antibodies. 
Automated serological assays and IgG avidity by means 
of ELISA. Out of the 200 samples, 136 were positive for IgG-VIDAS 
and 144 samples were positive for IgG-AxSYM. Ninety-seven serum 
samples were positive for IgM-VIDAS and 104 serum samples were 
positive for IgM-AxSYM. All other serum samples from patients with 
heterologous infections had negative specific IgG and IgM antibodies. 
For IgG avidity from VIDAS, out of 136 human serum samples, 91 had 
presented high-avidity IgG, nine had borderline-avidity IgG and 36 had 
low-avidity IgG. Among the IgG avidity results from ELISA, out of 136 
human serum samples, 90 samples had high-avidity IgG, eight had 
borderline-avidity IgG and 38 had low-avidity IgG. 
Kinetics of ESA production. During the first 12 hours of 
infection, the number of extracellular tachyzoites declined, and 
no host cells could be detected. During the next 12 hours, there 
was an increase in parasite numbers, and dead host cells were 
observed. The tachyzoites forms remained intact before and 
after inoculation, as observed by phase contrast microscopy. The 
ESA concentration in supernatants harvest from cultures at each 
study time was estimated and detected as early as one hour after 
infection. Levels of ESA only rose significantly in cultures after three 
hours, reaching a maximum at the end of the study period. 
Immunoblotting of IgG antibodies against ESA antigens.
Out of the 200 serum samples, 136 were reactive and revealed the 
same reactivity against fractions of different molecular weights. 
The eight discordant serum samples with regard to specific IgG 
antibodies did not occur between VIDAS and AxSYM, and the serum 
samples from patients with heterologous infection did not present 
any reactivity to protein fractions of Toxoplasma gondii ESA. 
Avidity of IgG antibodies against ESAs by means of 
immunoblotting. Out of 136 human serum samples, 103 had 
high-avidity IgG and 33 samples had low avidity IgG against the 
30kDa fraction protein. Serum samples from acute recently infected 
patients had low avidity and the samples from non-acute and chronic 
patients had high avidity against the 30kDa fraction protein.
DISCUSSION
Serological evaluation of the time when Toxoplasma infection 
was acquired is of fundamental importance for pregnant women, 
since infection during pregnancy requires intervention and 
treatment. During this phase, both clinical manifestations and 
congenital toxoplasmosis may occur3. Several methods have 
been used to measure specific IgM antibodies as markers for 
toxoplasmosis infection4. However, in clinical practice, it is not 
unusual to observe persistent IgM antibodies for prolonged 
periods after the acute phase of infection1 4 6 20 22.
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Table 2 shows that, in our study, residual IgM antibodies 
were detected by VIDAS and AxSYM, and this was confirmed by 
the negative results found for IIF, IHA, high avidity tests (VIDAS) 
and clinical follow-up information (data not shown). IgM-VIDAS 
assays showed better performance (residual IgM n=64) than seen 
with AxSYM (residual IgM n=71). VIDAS showed high specificity 
and positive predictive values with regard to detecting specific IgM 
antibodies11. IgG avidity determination is an important serological 
marker that can be used to distinguish between acute and non-
acute disease in single serum samples, through confirming the 
presence or absence of residual IgM antibodies4 10 13 17.
Table 2 - Performance of automated assays for detecting residual IgM 
antibodies in the samples studied.
                  IgM antibodies
Automated assay positive (no) true positive (no) residual (no)
VIDAS 97 33 64
AXSYM 104 33 71
True positive: Serum sample exhibited specific IgM antibodies (titer >64) using IIF 
and IHA, low avidity of specific IgG antibodies and clinical compatibility with acute
recent toxoplasmosis. 
However, recent studies on the kinetics of IgG avidity in 
pregnant women have observed high avidity in pregnant women 
who had been infected for at least three to five months and low 
avidity one year after the acute phase18. In addition, significant 
numbers of patients present borderline avidity results22.
Based on clinical information (data not shown) and 
conventional serological assays, we analyzed ELISA avidity and 
VIDAS avidity to determine residual IgM antibodies. For this, 71 
serum samples were used to determine residual IgM and were 
subjected to avidity assays. The VIDAS and ELISA avidity assays 
showed similar performance in the panel of 71 residual IgM 
samples: respectively 60/71 and 59/71 samples presenting with 
high avidity. Borderline avidity results were observed in nine 
samples with VIDAS and in eight samples with ELISA (Table 3). 
Problems in measuring specific IgG antibodies have only 
rarely been observed in laboratory practice7. In our study too, 
we only observed false positive results for specific IgG antibodies 
in eight out of 200 samples analyzed, as confirmed by negative 
results found with IgG-IIF and IgG-IHA. In this panel of eight 
false positive IgG samples, 3/8 (37.5%) yielded positive results 
with IgG-AxSYM and 5/8 (62.5%) were borderline IgG according 
to both automated assays (VIDAS and AxSYM) (Table 4). False 
positive results in relation to specific IgG antibodies may lead to 
wrong interpretation and diagnosis of congenital toxoplasmosis6.
Development of different serological techniques has increased 
the difficulty in defining diagnoses, even in the presence of 
several markers in single serum samples, due to persistency in 
distinguishing between acute recent phases and non-acute recent 
phases.
In the Toxoplasma serology laboratory of the Palo Alto Medical 
Foundation, which is a diagnostic reference center, positive 
IgM results in pregnant women are confirmed by combining 
measurements of IgG, IgA, IgE antibodies and IgG avidity in serum 
samples obtained at various times during pregnancy. In public 
Table 3 - Comparison of residual IgM antibodies obtained from 
automated assays and IgG avidity tests for 71 serum samples.
       IgM residual serum samples
IgG avidity result           VIDAS avidity ELISA avidity ESA avidity
no % no % no %
Low 2 2.8 4 5.6 0
Borderline/indeterminate 9 12.7 8 11.3 0
High 60 84.5 59 83.1 71 100.0
Table 4 - Discordant results obtained using IIF, IHA, VIDAS and AXSYM 
for measuring Toxoplasma-specific IgG antibodies.
                           Toxoplasma gondii- specific ESA-specific
                                      IgG antibodies   IgG antibodies
Sample IIF IHA VIDAS AXSYM Immunoblot
Titer/cutoff Titer/cutoff UI/cutoff UI/cutoff
1 <1:16 (<1:16) <1:16 (<1:16) < 4.0 (<4.0) 20(<3.0) NR
2 <1:16 (<1:16) <1:16 (<1:16) < 4.0 (<4.0) 20(<3.0) NR
3 <1:16 (<1:16) <1:16 (<1:16) < 4.0 (<4.0) 27(<3.0) NR
4 <1:16 (<1:16) <1:16 (<1:16) 6.0 (<4.0) 10(<3.0) NR
5 <1:16 (<1:16) <1:16 (<1:16) 7.0 (<4.0) 3(<3.0) NR
6 <1:16 (<1:16) <1:16 (<1:16) 4.0 (<4.0) 3.5(<3.0) NR
7 <1:16 (<1:16) <1:16 (<1:16) 4.0 (<4.0) 4.0(<3.0) NR
8 <1:16 (<1:16) <1:16 (<1:16) 4.0 (<4.0) 3.0(<3.0) NR
NR = non-reactive, UI = international units, IIF= indirect immunofluorescence assay, 
IHA=indirect hemagglutination, ESA= excreted/secreted antigen.
clinics and some laboratories in Brazil, residual IgM antibodies 
are determined in single serum samples in combination with 
specific IgG antibodies and rarely with IgG avidity, due to the cost 
of equipment and reagents for performing this additional test. 
In this respect, the present study focused on the potential 
for diagnoses in single serum samples by using the avidity of IgG 
antibodies against tachyzoite ESAs. These constitute most of the 
circulating antigens in acutely infected humans, and thus are one 
of the first targets of the immune response5 12. Based on different 
studies, we have recently developed a technique for obtaining ESAs 
by incubating tachyzoites in human fibroblast cell cultures for a 
short period of time2 14. At the outset of our studies on Toxoplasma 
gondii ESA, our concern was to rule out the possibility that the 
antigens could have been obtained from lysis of parasites during 
the procedure to produce the antigen. The results relating to ESA
kinetics have indicated that the antigen obtained has a secretory 
or excretory origin. The kinetics of secretion-excretion show 
that ESAs can be detected within the first hour and reach their 
maximum concentrations within three hours of inoculation. This 
was similar to what had previously been observed by Hughes13
when they detected ESAs in serum during the initial period of 
infection.
Protein fractions, including P30, were recognized by IgG 
antibodies with the same reactivity patterns in patients with acute 
and non-acute disease, in agreement with the findings of Acebes1
and Meek18 (Figure 1). However, the samples that presented false 
positive results in relation to specific IgG antibodies in automated 
assays, and also the healthy individuals and individuals with other 
diseases, did not present reactivity of IgG antibodies against protein 
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Figure 1 - Antigenic profile of excreted/secreted antigens of Toxoplasma 
gondii recognized by specific IgG antibodies in serum samples from acute 
recent cases (A), non-acute recent case (B), cases of chronic infection 
(group C), healthy individuals (group D) and cases of other diseases 
(group E), as determined by immunoblot.
fractions of Toxoplasma gondii ESA, as seen using immunoblot 
(Figure 1). These results differed from those of Hafid8 and Meek18,
which were based on ESA obtained from African green monkey 
kidney cell cultures and from infected mice. 
The avidity performance of IgG against the protein fraction of 
ESA-P30 in the panel of 33 acute disease samples and 61 non-acute 
samples was reliable: 33/33 present low avidity and 61/61 present 
with high avidity, respectively. Three out of 36 serum samples with 
serological characteristics of acute diseases but without compatible 
clinical features present high avidity in assays of IgG avidity 
against ESA by means of immunoblot (Figure 1). In addition, no 
indeterminate results for assays of IgG avidity against ESA by means 
of immunoblot were observed in the present study (Figure 2). 
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Figure 2 - Antigenic profile of excreted/secreted antigens of Toxoplasma gondii
recognized by specific IgG antibodies in serum samples from acute recent 
cases (A), non-acute recent cases (B) and chronic infection cases (group 
C), as determined by immunoblot without or with 8M urea treatment. 
0 = without urea; 8 = 8M urea.
Our data do not agree with those in the study by Marcolino15,
which could not distinguish between patients with acute and non-
acute disease through analyzing IgG avidity against P30 obtained 
from the peritoneum of infected mice. Most commercial kits and 
in-house methods use tachyzoites grown in mouse or other cell 
cultures and this factor is probably associated with the intrinsic 
proprieties of the technique used. This would explain the better 
performance of assays of IgG avidity against ESA protein fractions 
obtained from human fibroblast culture in distinguishing between 
acute and non-acute disease. Our date suggest that IgG avidity against 
P30 (probably SAG-1) can be considered to be an immunological 
marker for distinguishing acute disease from non-acute disease, 
thereby confirming the presence of residual IgM antibodies obtained 
for automated assays in single serum samples. 
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